Understand the source comparison
NAD+ Results After 2 Weeks: Supplement Forms Comparison
NMN (oral capsule) 20–30% 250–1000mg daily Plasma NAD+ elevation detectable but inconsistent tissue uptake Direct precursor. One enzymatic step to NAD+ Works if dose compensates for first-pass loss NR (oral capsule) 30–40% 300–600mg daily Modest plasma increas
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- NMN (oral capsule)
- 20–30%
- 250–1000mg daily
- Plasma NAD+ elevation detectable but inconsistent tissue uptake
- Direct precursor. One enzymatic step to NAD+
- Works if dose compensates for first-pass loss
- NR (oral capsule)
- 30–40%
- 300–600mg daily
- Modest plasma increase; liver NAD+ rises before muscle
- Stable in stomach acid; converts via NRK pathway
- Better oral stability than NMN
- Sublingual NMN
- 50–60%
- 150–500mg daily
- Faster peak plasma levels but shorter duration
- Bypasses hepatic first-pass
- Requires holding under tongue 90+ seconds
- Injectable NMN/NR
- 90–95%
- 100–300mg per injection
- Sustained plasma elevation 8–12 hours; consistent tissue saturation
- Highest bioavailability; predictable dosing
- Gold standard for therapeutic protocols
- Liposomal NMN
- 40–50%
- 200–500mg daily
- Intermediate between oral and sublingual
- Phospholipid encapsulation protects from degradation
- Premium cost without proportional benefit over sublingual
- The functional takeaway: oral NMN at 500mg delivers roughly the same tissue NAD+ elevation as 150–200mg subcutaneous NMN, but with greater variability due to gut microbiome differences and food intake timing. Users chasing NAD+ results after 2 weeks who aren't seeing changes should evaluate delivery route before increasing dose.